Therefore, within the context of SCD, targeting of heme-mediated vascular TLR4 signaling, but not LPS-mediated TLR4 signaling, may be a strategy to prevent or decrease I/R injury while maintaining immune function. The gene discussed is TLR4; the disease is Schnyder corneal dystrophy.